Akebia Therapeutics Inc. (AX9)

Profile

https://www.akebia.com

Akebia Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients impacted by kidney disease. Its lead product, Vafseo (vadadustat), is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for treating anemia due to chronic kidney disease in adults on dialysis. The company also maintains a pipeline targeting rare kidney diseases, including praliciguat, an sGC stimulator in Phase 2 for biopsy-confirmed focal segmental glomerulosclerosis, and AKB-097, a tissue-targeted C3d-Factor H fusion protein complement inhibitor planned for Phase 2 basket studies across complement-mediated conditions such as IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Additional candidates like AKB-9090 address acute kidney injury associated with cardiac surgery. Akebia Therapeutics Inc. supports its portfolio through licensing agreements, such as for Vafseo in Europe, and engages in post-marketing studies to expand clinical understanding and patient access in the dialysis community. Headquartered in Cambridge, Massachusetts, the company plays a key role in addressing unmet needs in the nephrology sector with innovative oral therapies and targeted pipeline advancements.